The invention discloses application of < 18 > F-
lactitol in preparation of a
diabetic nephropathy detection product, and belongs to the technical field of biomedical detection. In order to solve the problem that the action and mechanism of STRs in the
kidney through SGLT2-dependent glucose
reabsorption and transport are not clear yet, 18F-labeled
lactitol is used, the in-vivo glucose level,
kidney pathology and SGLT2 expression are detected through PET / CT, and the
glucose uptake rate is labeled through in-vitro
fluorescence, so that the effect and mechanism of STRs in the
kidney through SGLT2-dependent glucose
reabsorption and transport are determined. The method is used for evaluating the glucose
reabsorption effect and mechanism of the STRs in STZ (
streptozotocin)-induced diabetic mice and HK-2 cells. The result shows that the 18F-
lactitol can be sensitively and specifically combined with the STRs, the biological distribution of the 18F-lactitol and the expression of the STRs in the kidney of a
diabetic mouse are obviously reduced, the expression of the SGLT2 is up-regulated, and the lactitol or siRNA-STRs can obviously reduce the influence of
high glucose on the expression of the STRs and the SGLT2 and
glucose absorption. Therefore, the STRs can be used as a new therapeutic target for diabetes, and the < 18 > F-lactitol labeled PET / CT can become a novel probe for detecting
diabetic kidney injury.